Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
ConclusionsEquivalent efficacy and similar pharmacokinetics, safety, and immunogenicity support bioequivalence of CT-P16 and EU-bevacizumab in patients with nsNSCLC.Trial registration numberNCT03676192.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Study